

PATENT
600-1-162CP1

#10
Gh
9/25/97

APPLICANT(S) : Jeffrey M. Friedman, et als. EXAMINER : G.D. Draper
SERIAL NO. : 08/599,974 ART UNIT : 1812
FILED : February 14, 1996
FOR : DB, THE RECEPTOR FOR LEPTIN, NUCLEIC ACIDS
ENCODING THE RECEPTOR, AND USES THEREOF

RECEIVED
SEP 14 1997

CERTIFICATE OF MAILING UNDER 37 CFR 1.8

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to the ASSISTANT COMMISSIONER FOR PATENTS, WASHINGTON, DC 20231 on September 2, 1997.

David A. Jackson, Reg. #26,742
(Name of Registered Representative)

David A. Jackson 9/2/97
(Signature and Date)

RESPONSE TO RESTRICTION REQUIREMENT
UNDER 35 U.S.C. §121

ASSISTANT COMMISSIONER FOR PATENTS
WASHINGTON, D.C. 20231

Dear Sir:

This is in response to a Requirement for Restriction mailed March 31, 1997 requiring Applicant to elect between the following groups of claims for further prosecution:

Group I - Claims 1-14, 63, 66, drawn to various Ob receptor proteins, several point mutations and various compositions, classified in classes 530 and 514 or possibly 424, subclasses 350, 2+ and 401 respectively.

Group II - Claims 15-19, drawn to antigenic fragments and derivative thereto (Polymer conjugates), classified in classes 530, 424 subclasses 326+ and 185.1 respectively.

Group III - Claims 20-28, 34-48, 51-52, drawn to nucleic acids (NA) encoding Ob receptors (ObR), vectors, host cells and methods of making the variant forms of the OBR, classified in classes 435 and 536, subclasses 69.1+ and 23.5 respectively.

Group IV - Claims 29-33, 49-50 drawn to various partial nucleic acid pieces, such as oligo's (various different oligo's), antisense and ribozymes, classified in classes 514 and 536, subclasses 44+ and 24.3+ respectively-depending on the length and use of these products.

Group V - Claims 53-58 drawn to antibodies to ObR and hybridoma, classified in classes 530, subclass 388.22 and 70.21.

Group VI - Claims 59-62, drawn to methods of measuring leptin in various samples using antibodies, classified in class 435, subclass 7.1.


Group VII - Claims 64-65, drawn to methods of treating weight disorders such as obesity using OB-R compositions, classified in classes 514, subclasses 2+.

In accordance with 35 U.S.C. §121, Applicant hereby elects to prosecute the claims of Group III, Claims 20-28, 34-48, 51-52, drawn to nucleic acids (NA) encoding Ob receptors (ObR), vectors, host cells and methods of making the variant forms of the OBR, classified in Classes 435 and 536, subclasses 69.1+ and 23.5, with traversal.

The nucleic acid sequences embodied in the Group III claims are believed to be sufficiently related to the polypeptides and antigenic fragments thereof and other related materials including compositions, inasmuch as the nucleic acids are those which would code for the expression of the proteins in question. Likewise, any corresponding methods of use of the nucleic acids or their corresponding proteins, would relate to the specific nucleic acid sequences or fragments thereof that are placed in such use. Accordingly, examination of the claims as a unit, or at least a partial withdrawal of the Requirement for Restriction is believed to be in order.

In view of the above, early action on the merits is courteously solicited.

Respectfully submitted,



DAVID A. JACKSON
Attorney for Applicant
Registration No. 26,742

KLAUBER & JACKSON
411 Hackensack Avenue
Hackensack, NJ 07601
(201) 487-5800